Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024.Third Quarter 2024 Financial Results: Revenue of $0.6 million, which declined from$2.5 million during the prior year primarily due to timing of grant revenue recognition. Grant revenue totaled $0.4 million while product revenue totaled$0 ...